Following FDA approval, Zepbound remains under continuous post-marketing surveillance through the FDA Adverse Event Reporting System (FAERS)
Other Warnings for SEMALIX 7 TABLET Before taking SEMALIX 7 TABLET, inform your doctor if you: Have or have had pancreatic problems Have a history of diabetes-related vision problems (diabetic retinopathy) Are planning to undergo or have recently undergone surgery Experience severe and persistent abdominal pain Have low blood sugar (hypoglycaemia) Notice sudden changes in vision Have delayed gastric emptying (gastroparesis) Have gastrointestinal issues, such as severe vomiting, diarrhoea, or dehydration Have gallbladder problems Who should not take SEMALIX 7 TABLET SEMALIX 7 TABLET is not recommended for use if you: Have a personal or family history of medullary thyroid carcinoma (MTC) Have an endocrine disorder known as Multiple Endocrine Neoplasia syndrome type 2 (MEN2) Have type 1 diabetes Have developed diabetic ketoacidosis Drug - Drug interaction Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements
Both treatments serve a dual purpose for GLP-1 patients
FDA in September 2014, has continually expanded its indications to 40 approved and over 100 in research
Phase IIb, randomized, double-blind trial of GC4419 versus placebo to reduce severe oral mucositis due to concurrent radiotherapy and cisplatin for head and neck cancer
Women with T-score below -2.5 (osteoporosis) on DEXA who also need weight loss should discuss the HRT-plus-GLP-1 combination with a clinician, with annual DEXA monitoring and adequate calcium (1 to 200 mg/day) and vitamin D3 (1,500-2 to 000 IU/day) supplementation [39]
